Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
What GLP3 Planner Can Help You Understand Drug concentration curves: See how levels rise and fall between injections Steady state timing: Know when to expect stable drug levels Dose comparison: Compare different titration schedules side-by-side Microdosing modeling: Visualize split-dose protocols Shareable schedules: Create URLs to discuss your protocol with providers Plan Your Retatrutide Protocol Use our free calculator to model your retatrutide dosing schedule with pharmacokinetic projections
Weight loss exceeding this rate over several weeks may warrant dose adjustment or additional nutritional support
GLP-1 drugs, now used globally, are a staple for weight and diabetes treatment
The analysis also drew on linked electronic health record and prescription-dispensing data, and included obesity treatment at both specialist and generalist care settings
